intoxicant.wiki2catechol4school
Substance

Ublituximab

Original Wikipedia articleen.wikipedia.org/wiki/Ublituximab revision used (24 October 2026)

Why a "revision used" link? Anyone can edit Wikipedia at any time, so the article you open today may not say what it said when we read it. This link opens the exact version we read on 24 October 2026, frozen as it was. It is the only way to check that every quote on this page matches its source word for word. Newer versions may correct or change things. When we re-check this page against a newer version, the edit log records it. How we cite

Overview

Ublituximab, sold under the brand name Briumvi, is an immunomodulator used for the treatment of multiple sclerosis. It is a CD20-directed cytolytic monoclonal antibody.[1] WP

The most common adverse reactions include infusion reactions, including fever, chills, headache, influenza-like illness, elevated heart rate, nausea, throat irritation, reddening of the skin (erythema) and an anaphylactic (allergic) reaction; infections including serious and fatal bacterial, fungal, and new or reactivated viral infections and reduction in immunoglobulins.[2] WP

It was approved for medical use in the United States in December 2022, and in the European Union in May 2023.[3][4][5] WP

Uses, dosage and effects

Medical uses

Ublituximab is indicated for the treatment of relapsing forms of multiple sclerosis.[1][5] WP

History

History

Ublituximab was designed as part of a research program by the French Laboratory of Fractionation and Biotechnology, with the initial objective of addressing a clinical need in chronic B-lymphocytic leukemia. The design of ublituximab has been optimized to enhance the activation of killer immune cells while minimizing side effects, through modifications to its structure and glycosylation. After clinical trials confirming its strong cytotoxic activity and ability to eliminate B cells, the development of ublituximab was pursued by the American biopharmaceutical company TG Therapeutics.[6][7] WP

The US Food and Drug Administration approved ublituximab based on evidence from two clinical trials of 1,093 participants with relapsing forms of multiple sclerosis. The trials were conducted at 110 of sites in 10 countries in North America and Europe. The trials were used to assess both efficacy and safety of ublituximab. Participants received ublituximab or teriflunomide for up to 96 weeks. Neither the participants nor the health care providers knew which treatment was being given until the trials were completed. The benefit of ublituximab was evaluated based on the annualized relapse rate, or the number of relapses per year, over the treatment period.[2] WP

Legal status

Legal status

Ublituximab was approved for medical use in the United States in December 2022, and in the European Union in May 2023.[1][5][8][9] WP

Names

Ublituximab is the international nonproprietary name (INN).[10] WP

Ublituximab is sold under the brand name Briumvi.[5] WP

Chemistry

Awaiting sourceFormula, structure and identifiers from PubChem.

Harm reduction information

No harm reduction data is on file for this compound yet. That means no dose, timing or combination data from PsychonautWiki or TripSit. Please don't guess a dose from similar compounds. If you have taken it and feel unwell, contact emergency services or a poison control center.

Awaiting sourceChecked against PsychonautWiki and TripSit as each pull runs. This box is replaced as soon as a source has data.

User reports

Erowid erowid.org

Listings
Awaiting sourceExperience Vault listing and report categories.
Top stories
Awaiting sourceShort summaries of the most-read reports, each linked, saying only what the report says.

Bluelight bluelight.org

Listings
Awaiting sourceTrip report threads and this substance's discussion forum.
Top stories
Awaiting sourceShort summaries of the most-read reports, each linked, saying only what the report says.

Reddit reddit.com

Listings
Awaiting sourceTrip report posts and the relevant subreddits.
Top stories
Awaiting sourceShort summaries of the most-read reports, each linked, saying only what the report says.

Pop culture

No references added yet.

Add a reference

Registered users can add songs, films, books, shows, games and art about this substance. Link a source that names the substance, such as the work's Wikipedia article, a review or an interview, not only the work itself. Entries are voted on and moderated like every other value on this page.

Opens when accounts launch.

Sources

  1. Journal / agency Briumvi- ublituximab injection, solution, concentrate. 19 January 2023
  2. Journal / agency Drug Trials Snapshots: Briumvi. 28 December 2022
  3. Journal / agency Drug Approval Package: Briumvi. 6 February 2023
  4. Journal / agency Lee A. Ublituximab: First Approval. Drugs. April 2023. doi:10.1007/s40265-023-01854-z · PMID 36920653
  5. Journal / agency Briumvi EPAR. 13 July 2023
  6. Journal / agency Romeuf C, Dutertre CA, Garff-Tavernier M, Fournier N, Gaucher C, Glacet A, Jorieux S, Bihoreau N, Behrens CK, Beliard R, Vieillard V, Cazin B, Bourel D, Prost JF, Teillaud JL, Merle-Beral H. Chronic lymphocytic leukaemia cells are efficiently killed by an anti-CD20 monoclonal antibody selected for improved engagement of FcgammaRIIIA/CD16. British Journal of Haematology. March 2008. doi:10.1111/j.1365-2141.2007.06974.x · PMID 18302712
  7. Journal / agency de Romeuf C. EMABling, une technologie stimulant l’activité effectrice des anticorps monoclonaux - Histoire et applications cliniques vingt ans après. Médecine/Sciences. 1 December 2019. doi:10.1051/medsci/2019220 · PMID 31903931
  8. Other TG Therapeutics Announces FDA Approval of Briumvi (ublituximab-xiiy). 28 December 2022
  9. Other Briumvi. 1 June 2023
  10. Journal / agency World Health Organization. International nonproprietary names for pharmaceutical substances (INN): recommended INN: list 66. WHO Drug Information. 2011

Text and values on this page are quoted from Wikipedia (CC BY-SA 4.0). Each value links to the exact revision it came from.